A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Melanoma Clinical Trial

— LIMIT  

Official title:

LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04464759
• Other study ID #: UPCC 01620
• Secondary ID: IRB#835033
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 21, 2020
• Est. completion date: October 30, 2025

Study information

• Verified date: October 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: Lydia Giles, BSN, RN
• Phone: 215-662-6389
• Email: lydia.giles[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.

Description:

There are three parts to this Phase 1/2 study in subjects with advanced melanoma:

Phase 1a will identify the MTD and preliminary safety of combination hydroxychloroquine and nivolumab therapy.

Phase 1b will identify the MTD and preliminary safety of hydroxychloroquine administered in conjunction with nivolumab and ipilimumab therapy

Phase 2 will assess the clinical efficacy of combination hydroxychloroquine and nivolumab therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: October 30, 2025
• Est. primary completion date: October 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological evidence of melanoma, unresectable Stage III or Stage IV, any genotype, and any programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status

• Phase 1a: nivolumab + HCQ: any prior treatment, or treatment naïve

• Phase 2: nivolumab + HCQ:

• - - Cohort 2a: prior immunotherapy in the adjuvant or metastatic setting is required

• - - Cohort 2b: anti-PD-1 Ab-naïve, but may have received any prior other therapy

• Phase 1b nivolumab + ipilimumab + HCQ: anti-PD-1 refractory

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• At least one measurable site of disease by RECIST 1.1 criteria that has not been previously irradiated.

• Fresh or archived primary or metastatic tissue available for submission for correlative analyses

• Negative serum pregnancy test within 28 days prior to commencement of dosing in premenopausal women. Negative urine pregnancy test within 24 hours of starting treatment.

• Able to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels

• Adequate baseline organ function

Exclusion Criteria:

• Known serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability to receive the protocol treatment with reasonable safety.

• Pregnant or breast-feeding.

• Patients with brain metastases treated with whole brain radiation that have been stable for 2 months are eligible; patients with brain metastases treated with gamma knife or surgery are allowed to participate after 2 weeks have elapsed since their procedure. Subjects are excluded if they have leptomeningeal disease or metastases causing spinal cord compression that are symptomatic or untreated or not stable for greater than or equal to 3 months (documented by imaging) or requiring corticosteroids greater than 20 mg prednisone equivalent daily.

• Must have discontinued active immunotherapy, chemotherapy, or investigational anticancer therapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study.

• All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values listed in protocol eligibility) must be less than or equal to Grade 1 or irreversible (hypophysitis) according to the Common Terminology Criteria for Adverse Events version 5 at the time of starting treatment. Patients that are asymptomatic on low dose maintenance hormone replacement delivered at a stable dose for prior toxicities are eligible.

• Prior or concurrent cancer therapy. Active immunotherapy, chemotherapy, or investigational anticancer therapy within 4 weeks prior to entering the study or oral targeted therapy within 2 weeks prior to entering the study

• Phase 2 nivolumab + HCQ Cohort B: No prior immunotherapy is permitted

• Patients known to be experiencing an objective partial response to immunotherapy at the time of study enrollment.

• History of malignancy other than disease under study within 3 years of study enrollment EXCEPT: history of completely resected non-melanoma skin cancer, or history of indolent second malignancies are eligible.

• Diagnosis of severe autoimmune disease requiring immunosuppressive medications. Patients with adrenal insufficiency on replacement dose steroids are eligible.

• History of interstitial lung disease or chronic pneumonitis unrelated to prior immunotherapy. Prior interstitial pneumonitis related to immunotherapy that was completely treated with no need for ongoing clinical management is allowed.

• Due to risk of disease exacerbation patients with porphyria or psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations.

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide.

• Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (i.e. phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of the start of the study treatment

• Current use of a prohibited medication as described in section on Potential for Drug-Drug Interaction.

• History or evidence of increased cardiovascular risk

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Nivolumab
Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
• Hydroxychloroquine
Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
• Ipilimumab
Combination of nivolumab, hydroxychloroquine and ipilimumab

Locations

Country	Name	City	State
United States	Abramson Cancer Center at University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Ravi Amaravadi, MD	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Maximum tolerated dose (MTD) - Number of Subjects with Dose-limiting Toxicities	To determine the MTD and preliminary safety of HCQ when administered in conjunction with one of the following treatments in patients with advanced melanoma: HCQ administered in combination with nivolumab; or; HCQ administered in combination with nivolumab and ipilimumab followed by maintenance nivolumab	From first dose of protocol treatment to 16 to 32 weeks
Primary	Phase 2: Objective Response Rate (ORR)	To assess the ORR as measured by RECIST v1.1. in subjects with advanced melanoma	12 months
Secondary	Progression-free survival	The time from protocol treatment start to disease progression, death due to any cause, or last contact alive and progression-free over 24 months	From start of treatment to first progression, death due to any cause or last patient contact alive and progression-free over 24 months
Secondary	1 year survival rate	Percentage of subjects alive at one year from start of treatment	From start of treatment to one year